Literature DB >> 32641433

Prognostic utility of triglyceride-rich lipoprotein-related markers in patients with coronary artery disease.

Ye-Xuan Cao1, Hui-Wen Zhang1, Jing-Lu Jin1, Hui-Hui Liu1, Yan Zhang1, Rui-Xia Xu1, Ying Gao1, Yuan-Lin Guo1, Cheng-Gang Zhu1, Qi Hua2, Yan-Fang Li3, Raul D Santos4, Na-Qiong Wu5, Jian-Jun Li5.   

Abstract

TG-rich lipoprotein (TRL)-related biomarkers, including TRL-cholesterol (TRL-C), remnant-like lipoprotein particle-cholesterol (RLP-C), and apoC-III have been associated with atherosclerosis. However, their prognostic values have not been fully determined, especially in patients with previous CAD. This study aimed to examine the associations of TRL-C, RLP-C, and apoC-III with incident cardiovascular events (CVEs) in the setting of secondary prevention of CAD. Plasma TRL-C, RLP-C, and total apoC-III were directly measured. A total of 4,355 participants with angiographically confirmed CAD were followed up for the occurrence of CVEs. During a median follow-up period of 5.1 years (interquartile range: 3.9-6.4 years), 543 (12.5%) events occurred. Patients with incident CVEs had significantly higher levels of TRL-C, RLP-C, and apoC-III than those without events. Multivariable Cox analysis indicated that a log unit increase in TRL-C, RLP-C, and apoC-III increased the risk of CVEs by 49% (95% CI: 1.16-1.93), 21% (95% CI: 1.09-1.35), and 40% (95% CI: 1.11-1.77), respectively. High TRL-C, RLP-C, and apoC-III were also independent predictors of CVEs in individuals with LDL-C levels ≤1.8 mmol/l (n = 1,068). The addition of RLP-C level to a prediction model resulted in a significant increase in discrimination, and all three TRL biomarkers improved risk reclassification. Thus, TRL-C, RLP-C, and apoC-III levels were independently associated with incident CVEs in Chinese CAD patients undergoing statin therapy.
Copyright © 2020 Cao et al.

Entities:  

Keywords:  apolipoprotein C-III; cardiovascular events; remnant-like lipoprotein particle-cholesterol; triglyceride-rich lipoprotein-cholesterol

Year:  2020        PMID: 32641433      PMCID: PMC7469882          DOI: 10.1194/jlr.RA120000746

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  43 in total

1.  Remnant lipoproteins induce proatherothrombogenic molecules in endothelial cells through a redox-sensitive mechanism.

Authors:  H Doi; K Kugiyama; H Oka; S Sugiyama; N Ogata; S I Koide; S I Nakamura; H Yasue
Journal:  Circulation       Date:  2000-08-08       Impact factor: 29.690

2.  Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association.

Authors:  Emelia J Benjamin; Paul Muntner; Alvaro Alonso; Marcio S Bittencourt; Clifton W Callaway; April P Carson; Alanna M Chamberlain; Alexander R Chang; Susan Cheng; Sandeep R Das; Francesca N Delling; Luc Djousse; Mitchell S V Elkind; Jane F Ferguson; Myriam Fornage; Lori Chaffin Jordan; Sadiya S Khan; Brett M Kissela; Kristen L Knutson; Tak W Kwan; Daniel T Lackland; Tené T Lewis; Judith H Lichtman; Chris T Longenecker; Matthew Shane Loop; Pamela L Lutsey; Seth S Martin; Kunihiro Matsushita; Andrew E Moran; Michael E Mussolino; Martin O'Flaherty; Ambarish Pandey; Amanda M Perak; Wayne D Rosamond; Gregory A Roth; Uchechukwu K A Sampson; Gary M Satou; Emily B Schroeder; Svati H Shah; Nicole L Spartano; Andrew Stokes; David L Tirschwell; Connie W Tsao; Mintu P Turakhia; Lisa B VanWagner; John T Wilkins; Sally S Wong; Salim S Virani
Journal:  Circulation       Date:  2019-03-05       Impact factor: 29.690

Review 3.  The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk.

Authors:  Pratik B Sandesara; Salim S Virani; Sergio Fazio; Michael D Shapiro
Journal:  Endocr Rev       Date:  2019-04-01       Impact factor: 19.871

4.  Remnant Lipoproteins Are Residual Risk Factor for Future Cardiovascular Events in Patients With Stable Coronary Artery Disease and On-Statin Low-Density Lipoprotein Cholesterol Levels <70 mg/dL.

Authors:  Yuki Fujihara; Takamitsu Nakamura; Takeo Horikoshi; Jun-Ei Obata; Daisuke Fujioka; Yosuke Watanabe; Kazuhiro Watanabe; Kiyotaka Kugiyama
Journal:  Circ J       Date:  2019-04-18       Impact factor: 2.993

5.  VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial.

Authors:  F M Sacks; P Alaupovic; L A Moye; T G Cole; B Sussex; M J Stampfer; M A Pfeffer; E Braunwald
Journal:  Circulation       Date:  2000-10-17       Impact factor: 29.690

6.  Apolipoprotein C-III predicts cardiovascular mortality in severe coronary artery disease and is associated with an enhanced plasma thrombin generation.

Authors:  O Olivieri; N Martinelli; D Girelli; F Pizzolo; S Friso; F Beltrame; V Lotto; L Annarumma; R Corrocher
Journal:  J Thromb Haemost       Date:  2009-12-11       Impact factor: 5.824

7.  Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial.

Authors:  Robert P Giugliano; Terje R Pedersen; Jeong-Gun Park; Gaetano M De Ferrari; Zbigniew A Gaciong; Richard Ceska; Kalman Toth; Ioanna Gouni-Berthold; Jose Lopez-Miranda; François Schiele; François Mach; Brian R Ott; Estella Kanevsky; Armando Lira Pineda; Ransi Somaratne; Scott M Wasserman; Anthony C Keech; Peter S Sever; Marc S Sabatine
Journal:  Lancet       Date:  2017-08-28       Impact factor: 79.321

8.  Loss-of-function mutations in APOC3 and risk of ischemic vascular disease.

Authors:  Anders Berg Jørgensen; Ruth Frikke-Schmidt; Børge G Nordestgaard; Anne Tybjærg-Hansen
Journal:  N Engl J Med       Date:  2014-06-18       Impact factor: 91.245

9.  Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial.

Authors:  Antonio J Vallejo-Vaz; Rana Fayyad; S Matthijs Boekholdt; G Kees Hovingh; John J Kastelein; Shari Melamed; Philip Barter; David D Waters; Kausik K Ray
Journal:  Circulation       Date:  2018-08-21       Impact factor: 29.690

10.  Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.

Authors:  Gregory G Schwartz; P Gabriel Steg; Michael Szarek; Deepak L Bhatt; Vera A Bittner; Rafael Diaz; Jay M Edelberg; Shaun G Goodman; Corinne Hanotin; Robert A Harrington; J Wouter Jukema; Guillaume Lecorps; Kenneth W Mahaffey; Angèle Moryusef; Robert Pordy; Kirby Quintero; Matthew T Roe; William J Sasiela; Jean-François Tamby; Pierluigi Tricoci; Harvey D White; Andreas M Zeiher
Journal:  N Engl J Med       Date:  2018-11-07       Impact factor: 91.245

View more
  3 in total

Review 1.  The Role of RNA-Targeted Therapeutics to Reduce ASCVD Risk: What Have We Learned Recently?

Authors:  Marcio H Miname; Viviane Z Rocha; Raul D Santos
Journal:  Curr Atheroscler Rep       Date:  2021-06-19       Impact factor: 5.113

2.  Positive Association between Triglyceride-Rich Lipoprotein Cholesterol and Diabetes Mellitus in Hypertensive Patients.

Authors:  Wei Zhou; Yu Yu; Lingjuan Zhu; Wangsheng Fang; Yu Tao; Minghui Li; Xiao Huang; Tao Wang; Huihui Bao; Xiaoshu Cheng
Journal:  Int J Endocrinol       Date:  2021-12-01       Impact factor: 3.257

Review 3.  New Insights into Non-Alcoholic Fatty Liver Disease and Coronary Artery Disease: The Liver-Heart Axis.

Authors:  Georgiana-Diana Cazac; Cristina-Mihaela Lăcătușu; Cătălina Mihai; Elena-Daniela Grigorescu; Alina Onofriescu; Bogdan-Mircea Mihai
Journal:  Life (Basel)       Date:  2022-08-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.